Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 1, 2022
Reporting Period: Event-based (June 1, 2022)
Business Context: The Company, a British Columbia corporation listed on Nasdaq (Symbol: INM), entered into material definitive agreements to raise capital through a registered direct offering and a concurrent private placement.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance. Key transaction metrics include:
- Aggregate Gross Proceeds: Approximately $5 million.
- Securities Issued (Offerings):
- 4,079,256 common shares (or pre-funded warrants) in a registered direct offering.
- 1,748,250 common shares (or pre-funded warrants) in a concurrent private placement.
- Purchase Price: $0.858 per share (or pre-funded warrant).
- Investment Options: Unregistered preferred investment options to purchase up to 5,827,506 common shares at an exercise price of $0.74 per share.
- Placement Agent Fees: 7.5% cash fee of gross proceeds plus 6.5% of aggregate shares placed in the offering as preferred investment options.
- Use of Proceeds: Pipeline development, commercial activities, and general working capital.
Material Changes and Agreements
The filing reports the following material changes and agreements:
- Securities Purchase Agreements: Entered into on June 1, 2022, with an institutional accredited investor. Closing is expected on or about June 6, 2022.
- Warrant Amendment Agreement: Existing warrants (4,480,771 shares) issued in 2020 and 2021 were amended in consideration for the investor's purchase of approximately $3.5 million of shares.
- Exercise Price Reduction: Lowered from a range of $2.848 to $5.11 to $0.74 per share.
- Lock-up Period: Amended warrants are not exercisable for six months following the closing date.
- Expiration Extension: Extended to seven years following the closing date.
- Beneficial Ownership Limitation: Provisions allow the investor to receive pre-funded warrants if purchasing shares would cause beneficial ownership to exceed 4.99% (or 9.99% at election).
Outlook, Risks, and Contingencies
- Outlook: Management intends to utilize net proceeds to advance the company's pipeline and commercial activities.
- Contingencies: The Warrant Amendment Agreement is subject to the consummation of the registered direct offering and the investor's satisfaction of its purchase commitment.
- Risks: The unregistered pre-funded warrants and investment options may not be offered or sold in the United States absent registration or an applicable exemption. The offering is subject to customary closing conditions.
- Unusual Items: The transaction involves a significant reduction in the exercise price of existing warrants and the issuance of new investment options with a lower exercise price ($0.74) than the current offering price ($0.858).
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 6, 2022) and confirmation of the $5 million gross proceeds.
- Review the impact of the warrant amendment on existing shareholders, specifically the dilution from the 4,480,771 amended warrants now exercisable at $0.74.
- Confirm the total number of shares outstanding post-closing, including the 5,827,506 shares underlying the new investment options.
- Check the final prospectus supplement filed with the SEC for the registered direct offering.
- Monitor the company's cash burn rate relative to the $5 million raised to assess runway for pipeline development.